术中地塞米松降低全关节置换术后再入院率且不影响血栓栓塞事件或感染风险
地塞米松组90天再入院率1.6% vs 2.5%(OR 0.57,95%CI 0.36-0.90,P=0.016),临床有症状静脉血栓栓塞事件率0.1% vs 0.2%(P=0.353),假体周围感染与死亡率无差异。
要点
- 术中单次静脉地塞米松8-10 mg与90天再入院率降低独立相关(1.6% vs 2.5%,OR 0.57)。
- 地塞米松组临床有症状静脉血栓栓塞事件率0.1% vs 0.2%,单因素分析未达统计学显著(P=0.353)。
- 假体周围感染率与90天死亡率两组无差异。
核心结论
- 术中单次低剂量地塞米松与临床有症状静脉血栓栓塞事件减少无关,但可能作为安全有效的辅助用药降低90天再入院率。
研究设计与样本
- 单中心2009至2016年接受初次单侧全关节置换的患者,未接受地塞米松组6617例,术中静脉接受单次地塞米松8-10 mg组1293例,证据等级为III级。
主要发现
- 临床有症状静脉血栓栓塞事件总发生率地塞米松组0.1% vs 未接受地塞米松组0.2%,单因素分析未达统计学显著(P=0.353)。
- 多因素分析中,仅体重指数(OR 1.13,95%CI 1.03-1.24,P=0.006)和较长住院时间(OR 1.16,95%CI 1.06-1.28,P=0.001)与静脉血栓栓塞事件相关;地塞米松的OR为0.31(95%CI 0.04-2.36,P=0.319)。
- 静脉使用地塞米松与90天再入院率降低独立相关(1.6% vs 2.5%;OR 0.57,95%CI 0.36-0.90,P=0.016)。
- 假体周围感染率或死亡率两组无差异。
临床怎么用
- 作者认为术中单次低剂量地塞米松可能作为安全有效的辅助用药降低90天再入院率,但原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of perioperative dexamethasone has been proven to reduce pain and shorten recovery for patients undergoing total hip and knee arthroplasty. However, the effect of these medications on 90-day readmissions and the rates of clinically significant venous thromboembolic events (VTE) after total joint arthroplasty (TJA) remains unknown. METHODS: Patients undergoing unilateral, primary total joint arthroplasty between 2009 and 2016 in a single institution were identified. There were 6617 patients who did not receive dexamethasone intraoperatively compared to 1293 patients who received a single, intraoperative, intravenous dose of dexamethasone (8-10 mg). The primary outcomes were the rate of clinically significant VTE and 90-day readmission. Secondary outcomes included wound complications, periprosthetic joint infection, and 90-day mortality. RESULTS: While the overall rate of clinically symptomatic VTE was lower in the dexamethasone group, this did not reach significance in a univariate analysis (0.1% vs 0.2%, P = .353). Only body mass index (odds ratio [OR], 1.13; 95% confidence interval [CI], 1.03-1.24; P = .006) and longer length of stay (OR, 1.16; 95% CI, 1.06-1.28; P = .001) were associated with VTE in the multivariate analysis (OR, 0.31; 95% CI, 0.04-2.36; P = .319). However, the use of intravenous dexamethasone was independently associated with a reduction in 90-day readmission rate (1.6% vs 2.5%; OR, 0.57; 95% CI, 0.36-0.90; P = .016). There was no difference in the rate of periprosthetic joint infection or mortality. CONCLUSION: A single, intraoperative, low dose of dexamethasone is not associated with a reduction in clinically significant VTE but may be a safe and effective adjunct medication to lower 90-day readmission rates. LEVEL OF EVIDENCE: Level III.
引用
- Klement MR, Wilkens HS, Fillingham YA, et al. Intraoperative Dexamethasone Reduces Readmission Rates Without Affecting Risk of Thromboembolic Events or Infection After Total Joint Arthroplasty. J Arthroplasty. 2018. PMID: 29885970. doi:10.1016/j.arth.2018.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。